Skip to main content
OpenTrials
Completed

NCT Number: NCT04267536

An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. RA can reduce the ability to perform everyday tasks. This study assesses whether C-reactive protein (CRP)-level has an impact on achieving remission with upadacitinib when used alone or in combination with methotrexate (MTX). This study will also assess the reduction in pain, morning stiffness, fatigue, functionality, health status and impact of RA.

CRP is an indicator of inflammation and often used for disease activity monitoring during RA treatment. Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate. This study has two groups - upadacitinib monotherapy and combination. Adult participants with moderate to severe RA will be enrolled. Around 500 participants will be enrolled in the study in multiple sites within Germany.

Participants will receive upadacitinib alone or in combination with MTX per their physicians' usual prescription. Individual data will be collected for 12 months.

No additional study-related tests will be conducted during the routine physician visits. Only data which are routinely collected during a regular visit will be utilized for this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis (RA) Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Praxis Dr. Rinaldi /ID# 218424, Ulm, Baden-Wurttemberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of moderate to severe active rheumatoid arthritis (RA) upon judgment of the treating physician.
  • Swollen Joint Count (SJC) >= 3 of 28 joints of the Disease Activity Score (DAS)28.
  • Measurement of C-Reactive Protein (CRP)-level at Baseline (BL) or <= 4 weeks prior to BL at a timepoint when the Prednisolone equivalent dose of Glucocorticoid treatment was <= 10 mg/day for at least 7 days.
  • Upadacitinib treatment is indicated as per local Summary of Product characteristics (SmPC).
  • Decision on the treatment with Upadacitinib was made prior to any decision to approach the patient to participate in this study.

Exclusion criteria

  • Participants who cannot be treated with Upadacitinib according to the local Upadacitinib SmPC.
  • Prior treatment with Upadacitinib.
  • Treatment with Sarilumab or Tocilizumab within the last 8 weeks before the CRP level for inclusion was measured.
  • Participants currently participating in interventional research.
  • Participants who are unwilling or unable to complete the patient reported questionnaires.

Treatment and study plan

Primary outcomes

  1. Percentage of Participants Achieving Remission

    Time frame: 6 Months

    Remission is defined as clinical disease activity index (CDAI) <=2.8

Secondary outcomes

  1. Percentage of Participants Achieving Remission

    Time frame: Up to 12 Months

    Remission is defined as the disease activity score at 28 joints (DAS28)-C-Reactive protein (CRP)<2.6, DAS28- erythrocyte sedimentation rate (ESR)<2.6, simplified disease activity index (SDAI)<=3.3, CDAI<=2.8, Boolean.

  2. Percentage of Participants Achieving Low Disease Activity (LDA)

    Time frame: Up to 12 Months

    LDA is defined as DAS28-CRP<3.2, DAS28-ESR<3.2, SDAI <=11, CDAI<=10

  3. Mean Change From Baseline in CDAI

    Time frame: Up to 12 Months

    The CDAI is a validated measure of RA disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale (VAS) from 0 to 10 (cm), and global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm) were included in the CDAI score. Scores on the CDAI range from 0 (lowest disease activity) to 76 (highest disease activity).

  4. Mean Change From Baseline in SDAI

    Time frame: Up to 12 Months

    The SDAI is a validated measure of RA disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global disease activity assessed by the participant on a visual analogue scale from 0 to 10 (cm) , global disease activity assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein (mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 (lowest disease activity) to 86 (highest disease activity).

  5. Mean Change From Baseline in DAS28-CRP

    Time frame: Up to 12 Months

    The Disease Activity Score (DAS) 28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 (lowest disease activity) to 10 (highest disease activity).

  6. Mean Change From Baseline in DAS28-ESR

    Time frame: Up to 12 Months

    The Disease Activity Score (DAS) 28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 (lowest disease activity) to 10 (highest disease activity).

  7. Percentage of Participants Achieving Pain Reduction (Improvement by 30 %)

    Time frame: Up to 12 Months

    Improvement in pain reduction is assessed by numeric rating scale (NRS). The NRS of Pain sheet will be filled out in the office by participants at the designated visits.

  8. Percentage of Participants Achieving Pain Reduction (Improvement by 50 %)

    Time frame: Up to 12 Months

    Improvement in pain reduction is assessed by numeric rating scale (NRS). The NRS of Pain sheet will be filled out in the office by participants at the designated visits.

  9. Percentage of Participants Achieving Pain Reduction (Improvement by 70 %)

    Time frame: Up to 12 Months

    Improvement in pain reduction is assessed by numeric rating scale (NRS). The NRS of Pain sheet will be filled out in the office by participants at the designated visits.

  10. Mean Change From Baseline in Pain

    Time frame: Up to 12 Months

    The NRS of Pain sheet will be filled out in the office by participants at the designated visits.

  11. Percentage of Participants Achieving Fatigue Reduction (Improvement by 30 %)

    Time frame: Up to 12 Months

    Improvement in fatigue reduction is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.

  12. Percentage of Participants Achieving Fatigue Reduction (Improvement by 50 %)

    Time frame: Up to 12 Months

    Improvement in fatigue reduction is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.

  13. Percentage of Participants Achieving Fatigue Reduction (Improvement by 70 %)

    Time frame: Up to 12 Months

    Improvement in fatigue reduction is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.

  14. Mean Change From Baseline in Fatigue

    Time frame: Up to 12 Months

    Change in Fatigue is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.

  15. Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID)

    Time frame: Up to 12 Months

    RAID is a tool for assessment of disease activity purely based on a patient questionnaire.

  16. Percentage of Participants Achieving RAID <= 3

    Time frame: Up to 12 Months

    RAID is a tool for assessment of disease activity purely based on a patient questionnaire.

  17. Percentage of Participants Achieving RAID > 3 and <=4

    Time frame: Up to 12 Months

    RAID is a tool for assessment of disease activity purely based on a patient questionnaire.

  18. Percentage of Participants Achieving RAID > 4 and <=6

    Time frame: Up to 12 Months

    RAID is a tool for assessment of disease activity purely based on a patient questionnaire.

  19. Percentage of Participants Achieving RAID > 6

    Time frame: Up to 12 Months

    RAID is a tool for assessment of disease activity purely based on a patient questionnaire.

  20. Change From Baseline in Morning Stiffness Severity

    Time frame: Up to 12 Months

    Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe".

  21. Change From Baseline in Morning Stiffness Duration

    Time frame: Up to 12 Months

    The duration of morning stiffness was reported by participants as the average daily length during the past week in minutes (from time of awaking to time of maximal improvement).

  22. Change From Baseline in Functionality (FFbH)

    Time frame: Up to 12 Months

    A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score.

  23. Change From Baseline in Patient Health Questionnaire (PHQ-9)

    Time frame: Up to 12 Months

    The PHQ-9 is a 9-item questionnaire for assessing the severity of depression. Each question is answered on a scale from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, where higher scores indicate more severe depression.

  24. Percentage of Participants With Minimal Clinically Important Difference (MCID) in PHQ-9

    Time frame: Up to 12 Months

    MCID is defined as the at least 5 points difference from baseline in PHQ-9. The PHQ-9 is a 9-item questionnaire for assessing the severity of depression.

  25. Percentage of Participants With Low Disease Activity (LDA) or Remission Without Actual Concomitant MTX

    Time frame: Up to 12 Months

    LDA is defined as DAS28 < 3.2, CDAI<=10, SDAI <11. Remission is defined as DAS28<2.6, CDAI<=2.8; Boolean Remission.

  26. Percentage of Participants With LDA or Remission With Actual Concomitant MTX

    Time frame: Up to 12 Months

    LDA is defined as DAS28 < 3.2, CDAI<=10, SDAI <11. Remission is defined as DAS28<2.6, CDAI<=2.8; Boolean Remission.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

UPwArds - Post Marketing Observational Study to Evaluate the Impact of CRP-Level on the Real World Effectiveness of UPadacitinib When Used in MonotherApy or in Combination With MTX in Patients With RheumatoiD ArthritiS

Acronym: UPWARDS

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Feb 13, 2020
Registry last updated
Jan 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.